Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.45 |
| ▸ | CCR3 | P51677 | 20/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229500 | 1.00 | HRH1 (0.45) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL3228745 | 0.90 | HRH1 (0.45) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL3228734 | 0.90 | HRH1 (0.45) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL8936533 | 0.88 | HRH1 (0.46) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL8936493 | 0.84 | HRH1 (0.42) | HRH1CCR3KCNH2 | |
| SCHEMBL8936546 | 0.82 | HRH1 (0.42) | HRH1CCR3KCNH2 | |
| SCHEMBL8934493 | 0.81 | MAOA (0.39) | HRH1CCR3KCNH2 | |
| SCHEMBL8936483 | 0.81 | MAOA (0.46) | HRH1CCR3KCNH2 | |
| SCHEMBL8936719 | 0.80 | HRH1 (0.42) | HRH1CCR3KCNH2 | |
| SCHEMBL8936664 | 0.80 | SMN1; SMN2 (0.48) | HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102187-B1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI SA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8461144-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | SANOFI (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8278294-B2 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase | SANOFI (FR) | 2012-10-02 | — | — | US | disclosed |
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | ROCK1, MYLK, ROCK2 | HRH1 975/4885CCR3 4267/4885KCNH2 2214/4885 |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | MYLK2, RHOT2, MYLK | HRH1 2358/4885CCR3 4713/4885KCNH2 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.